Literature DB >> 35699489

Ribavirin Use in Hospitalized Children.

William R Otto1,2, Giyoung Lee2, Cary W Thurm3, Adam L Hersh4, Jeffrey S Gerber1,2,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35699489      PMCID： PMC9426859          DOI： 10.1093/jpids/piac039

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   5.235


× No keyword cloud information.
  5 in total

1.  Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation.

Authors:  Lily Li; Robin Avery; Marie Budev; Sherif Mossad; Lara Danziger-Isakov
Journal:  J Heart Lung Transplant       Date:  2012-05-22       Impact factor: 10.247

Review 2.  Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature.

Authors:  Tracy P Trang; Meghan Whalen; Alexandra Hilts-Horeczko; Sarah B Doernberg; Catherine Liu
Journal:  Transpl Infect Dis       Date:  2018-03-31       Impact factor: 2.228

3.  American Academy of Pediatrics Committee on Infectious Diseases: Use of ribavirin in the treatment of respiratory syncytial virus infection.

Authors: 
Journal:  Pediatrics       Date:  1993-09       Impact factor: 7.124

4.  Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients.

Authors:  J R Marcelin; J W Wilson; R R Razonable
Journal:  Transpl Infect Dis       Date:  2014-03-13       Impact factor: 2.228

5.  Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients.

Authors:  Farnaz Foolad; Samuel L Aitken; Terri Lynn Shigle; Amrita Prayag; Shashank Ghantoji; Ella Ariza-Heredia; Roy F Chemaly
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.